We Expect THLD Shares To Perform Well Into 2015, Says H.C. Wainwright
In a research report issued today, H.C. Wainwright analyst Andrew Fein initiated coverage on Threshold Pharmaceuticals (NASDAQ:THLD) shares, with a Buy rating and a $12 price target.
Fein wrote, “We expect THLD shares to perform well into 2015, as a stream of preclinical and clinical updates at the major oncology meetings in 2H14 (ESMO, EORTC, ASH) first continues to sensitize investors on the wide applicability of TH-302 in oncology, and then focuses their attention on the value-driving readout of the sarcoma and pancreatic cancer pivotal studies in mid-2015 and early 2016, respectively.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Andrew Fein has a total average return of 18.6% and a 69.2% success rate. Fein is ranked #380 out of 3270 analysts.